Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 0.00 |
|
|||||
| News | - |
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Arch Therapeutics Inc (QB) | ARTHD | OTCMarkets | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.60 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.60 | 3.60 |
| Trades | Shares Traded | Average Volume |
|---|---|---|
| 0 | 0.00 | - |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 3.60 | USD |
Arch Therapeutics Inc (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 4.63M | 1.29M | 1.02M | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Arch Therapeutics (QB) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 4/03/2024 | 16:07 | Edgar (US Regulatory) | Form 8-K - Current report |
| 3/18/2024 | 15:29 | Edgar (US Regulatory) | Form 8-K - Current report |
| 3/01/2024 | 15:31 | Edgar (US Regulatory) | Form 8-K - Current report |
| 3/01/2024 | 15:30 | Edgar (US Regulatory) | Form 10-K/A - Annual report [Section 13 and 15(d), not S-K.. |
| 2/20/2024 | 16:30 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 2/15/2024 | 15:30 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form.. |
| 2/07/2024 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/22/2024 | 11:39 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
| 1/12/2024 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/11/2024 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/29/2023 | 15:30 | Edgar (US Regulatory) | Form NT 10-K - Notification of inability to timely file Form.. |
| 12/15/2023 | 15:31 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ARTHD Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 5.96 | 7.00 | 3.01 | 4.90 | 1,957 | -2.36 | -39.60% |
| 5 Years | 5.96 | 7.00 | 3.01 | 4.90 | 1,957 | -2.36 | -39.60% |
Arch Therapeutics (QB) Description
| Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch's products authorized for commercial marketing are AC5 Advanced Wound System and AC5 Topical Hemostat. Arch's development stage product candidates include AC5-GTM and AC5 Surgical Hemostat, among others. |
